晚期非小细胞肺癌治疗的新机遇和挑战

文章预览

SCI 11 September 2024 New promises and challenges in the treatment of advanced non-small-cell lung cancer （IF: Lancet, 98.4） Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S, Hirsch FR. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024 Aug 24;404(10454):803-822.  Correspondence to: Fred R Hirsch, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, New York City, NY 10029, USA fred.hirsch@mssm.edu Targeted therapies and immunotherapies have radically improved treatment for advanced non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver mutations continue to evolve over multiple generations to enhance effectiveness and tackle drug resistance. Immune checkpoint inhibitors remain integral for the treatment of NSCLCs that do not have specific actionable genetic mutations. Antibody–drug conjugates and bispecific antibodies are being integrated into treat ………………………………